First AD

Second AD

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Expert Perspectives on the Utility of Real-World Data in the Management of Plaque Psoriasis

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Peer Exchange

Brad Glick, DO, AOCD, George Han, MD, PhD, and Neal Bhatia, MD, discuss year long term efficacy and safety data regarding the use of IL-23 inhibitors in patients with moderate to severe plaque psoriasis.

Long Term Efficacy And Safety Data: IL-23 Inhibitors in Patients with Moderate to Severe Plaque Psoriasis

Plaque Psoriasis: Current Expansion of the Therapeutic Landscape

Shifting Treatment Approaches to Plaque Psoriasis

Current Role of Topical Therapy for Plaque Psoriasis Treatment

Spectrum of Disease and Current Treatment Options for Plaque Psoriasis

Plaque Psoriasis: Escalating Treatment

Communication With Patients About Plaque Psoriasis Treatment

IL-23 inhibitors for Plaque Psoriasis Treatment  

Impact of Treatment Mode of Delivery on Patient Adherence and Plaque Psoriasis Treatment Selection

Long-Term Persistence of Biologic Treatment Options for Plaque Psoriasis

IL-23 Inhibitors and the Current Treatment Landscape for Plaque Psoriasis

BMI and Background Comorbidities that Impact Plaque Psoriasis Treatment

Plaque Psoriasis: Older Populations and Skin of Color

Looking Ahead at Clinical Trial Metrics for Plaque Psoriasis

Plaque Psoriasis: Future Therapeutic Pipeline